title: Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
abstract: Sarcomas are a group of rare solid tumours arising from mesenchymal or connective tissue. This review focuses on soft tissue sarcoma and covers general topics such as the epidemiology, age distribution, site of disease, histogenesis, histological subtypes, prognosis and outcome of treatment. In more detail, the article reviews current systemic treatment standards and selected adverse events of agents such as doxorubicin, ifosfamide, trabectedin and pazopanib, and briefly highlights some drugs that are used off-label in specific subtypes of sarcoma.
authors.affiliation: Department of General Medical Oncology and Laboratory of Experimental Oncology, Leuven Cancer Institute, KU Leuven, Belgium.
authors.forename: Patrick
authors.initials: P
authors.lastname: Schöffski
authors.forename: Jasmien
authors.initials: J
authors.lastname: Cornillie
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Wozniak
authors.forename: Haifu
authors.initials: H
authors.lastname: Li
authors.forename: Daphne
authors.initials: D
authors.lastname: Hompes
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D004149:Dioxoles / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage*; D007191:Indazoles; D011743:Pyrimidines / Q000008:administration & dosage*; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology*; D013449:Sulfonamides / Q000008:administration & dosage*; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage*; D000077606:Trabectedin; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004149:Dioxoles; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; D044005:Tetrahydroisoquinolines; C516667:pazopanib; D004317:Doxorubicin; D000077606:Trabectedin; D007069:Ifosfamide